CS
ESPR

Candriam SCA’s Esperion Therapeutics ESPR Stock Holding History

Candriam SCA’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-95,955
Closed -$3.57M – 822
2020
Q3 		$3.57M Sell
95,955
-20,849
-18% -$826K 0.03% 405
2020
Q2 		$5.99M Sell
116,804
-98,292
-46% -$4.11M 0.06% 300
2020
Q1 		$12.5M Hold
215,096
– – 0.14% 169
2019
Q4 		$12.8M Buy
+215,096
New +$9.67M 0.14% 170
2018
Q4 		– Sell
-30,000
Closed -$1.33M – 822
2018
Q3 		$1.33M Hold
30,000
– – 0.02% 575
2018
Q2 		$1.18M Hold
30,000
– – 0.02% 579
2018
Q1 		$2.17M Sell
30,000
-55,000
-65% -$4.04M 0.04% 464
2017
Q4 		$5.6M Buy
85,000
+5,000
+6% +$269K 0.1% 251
2017
Q3 		$4.01M Buy
80,000
+10,000
+14% +$482K 0.07% 311
2017
Q2 		$3.24M Buy
+70,000
New +$2.57M 0.06% 357
2016
Q4 		– Sell
-50,000
Closed -$693K – 676
2016
Q3 		$693K Hold
50,000
– – 0.02% 549
2016
Q2 		$494K Sell
50,000
-14,000
-22% -$232K 0.01% 551
2016
Q1 		$1.08M Sell
64,000
-11,000
-15% -$177K 0.03% 417
2015
Q4 		$1.67M Sell
75,000
-25,800
-26% -$651K 0.04% 325
2015
Q3 		$2.38M Sell
100,800
-59,200
-37% -$3.72M 0.06% 314
2015
Q2 		$13.1M Buy
160,000
+17,000
+12% +$1.66M 0.27% 103
2015
Q1 		$13.2M Buy
143,000
+88,000
+160% +$5.68M 0.27% 103
2014
Q4 		$2.22M Buy
+55,000
New +$1.68M 0.05% 346

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Candriam SCA's ESPR Position: Q4 2020 in Review

Candriam SCA sold out of Esperion Therapeutics (ESPR) in Q4 2020, closing a stake of 95,955 shares — an estimated $3.57M sold.

Candriam SCA first reported a position in ESPR in Q4 2014 and held it in 18 quarters. The position peaked at $13.2M in Q1 2015. 157 funds tracked by Wall St. Rank hold ESPR as of Q4 2020.

  • Candriam SCA reported no remaining Esperion Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Candriam SCA sold 95,955 Esperion Therapeutics shares in Q4 2020, an estimated $3.57M.
  • Candriam SCA first reported a position in Esperion Therapeutics in Q4 2014 and held it in 18 quarters.
  • Candriam SCA's Esperion Therapeutics position peaked at $13.2M in Q1 2015.
  • 157 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2020.

Based on Candriam SCA's 13F filing for Q4 2020, filed 22 Jan 2021.